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Abstract
The vascular fibrinolytic system is crucial for spontaneous lysis of blood clots. Plasminogen activator inhibitor 1 (PAI-1), the
principal inhibitor of the key fibrinolytic enzyme tissue-type plasminogen activator (tPA), is present in platelets at high
concentrations. However, the majority of PAI-1 stored in platelets has been considered to be inactive. Our recent finding
(Brogren H, et al. Blood 2004) that PAI-1 de novo synthesized in platelets remained active for over 24 h, suggested that PAI-1
stored in the a-granules might be active to a larger extent than previously reported. To re-evaluate this issue, we performed
experiments where the fraction of active PAI-1 was estimated by analyzing the tPA-PAI-1 complex formation. In these
experiments platelets were lysed with Triton X-100 in the presence of serial dilutions of tPA and subsequently the tPA-PAI-1
complex was evaluated by Western blot. Also, using a non-immunologic assay, tPA was labeled with
125I, and
125I-tPA and
125I-tPA-PAI-1 was quantified by scintigraphy. Interestingly, both methods demonstrated that the majority (.50%) of
platelet PAI-1 is active. Further analyses suggested that pre-analytical procedures used in previous studies (sonication or
freezing/thawing) may have substantially reduced the activity of platelet PAI-1, which has lead to an underestimation of the
proportion of active PAI-1. Our in vitro results are more compatible with the role of PAI-1 in clot stabilization as
demonstrated in physiological and pathophysiological studies.
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Introduction
In vivo clot lysis results primarily from activation of the
fibrinolytic system by tissue-type plasminogen activator (tPA)
released from the vascular endothelium. The thrombolytic activity
of tPA is regulated by specific inhibitors, the most important of
which is plasminogen activator inhibitor 1 (PAI-1). Blood clots
contain large amounts of PAI-1 that may originate from a-
granules of activated platelets [1]. Immuno-histochemical studies
have shown that platelet-rich arterial clots contain 2 to 3 fold more
PAI-1 than venous clots [2,3], and there is a close correlation
between the relative PAI-1 content of a clot and its resistance to
thrombolysis [4]. The importance of platelet PAI-1 is further
supported by in vitro clot assays on platelets from a patient with
complete lack of PAI-1 expression [5], as well as by studies on
thrombi generated in the Chandler loop experimental thrombosis
model [6,7]. Furthermore, studies in transgenic mice have shown
that PAI-1 not only influences the resistance to thrombolysis but
also the rate of progression of thrombus formation following
vascular injury [8].
These observations, that clearly indicate an important physio-
logical function of platelet PAI-1, have been difficult to reconcile
with the fact that most previous studies have shown that only 2%
to 5% of PAI-1 in platelets is active e.g. [9,10,11,12]. Therefore,
the role of platelet PAI-1 for clot stabilization has remained
enigmatic. Following a recent study of the de novo synthesis of PAI-
1 in platelets [13], we unexpectedly found that in a functional
assay in which platelets were lysed in the presence of tPA, not only
the small fraction of newly synthesized PAI-1, but also the majority
of PAI-1 already present in the platelet apparently was able to
complex-bind tPA. This observation suggested that the main
proportion of platelet PAI-1 was active, but that pre-analytical
conditions and/or the timing of the addition of tPA might be
critical for correct assessment of the true PAI-1 activity.
In the studies cited above, platelets were lysed by ultrasound
sonication [9,10,12]. However, it has been demonstrated that
sonication per se may denature proteins and cause epitopes to be
destroyed or hidden due to aggregation [14]. Thus, it might be
possible that sonication used in the preparation of platelet lysates
may induce latency transition, or protein damage that reduces the
activity of PAI-1. Other commonly used platelet lysis protocols
e.g. freezing/thawing or use of Triton X-100 can also accelerate
inactivation of PAI-1 [15,16]. Unless tPA is present already
during lysis of the platelets, it might be possible that these
procedures have lead to an underestimation of PAI-1 activity or,
at least, caused a great variability depending on how much the
inactivation rate is affected. Indeed, in a study of Wiman and co-
workers on Triton X-100 lysed platelets, substantially higher PAI-
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[17,18].
In the present work we reinvestigated the issue of the activity of
PAI-1 stored in washed platelet using a functional approach,
studying the tPA-PAI-1 complex formation with two methods.
Due to the conformational changes in the PAI-1 molecule
depending on its state, detection and quantification using
antibodies is very intricate. To avoid the difficulties of immuno-
chemical detection of the diverse PAI-1 molecule, detection of
tPA, either free or in complex with PAI-1, was used to determine
the amount of active PAI-1. We also investigated the effect of
different lysis methods on PAI-1 activity. The results show that the
majority of platelet PAI-1 (.50%) is active and that the previous
observations of low PAI-1 activity may be underestimations due to
inactivation during the pre-analytical procedures.
Results
Total PAI-1 antigen in washed platelets
ELISA was used to determine the total amount of PAI-1 antigen
in platelets, and the mean PAI-1 concentration was 0.79 (60.13)
ng/10
6 platelets. Initially we used three different commercially
available ELISA kits and the total mean of all three assays was
0.64 (60.04) ng/10
6 platelets. However, here we choose to report
the results from the kit with the highest antigen concentrations to
circumvent an overestimation of the level of activity.
PAI-1 activity in lysed washed platelets determined by
Western blot
Western blot analysis of platelet lysates was performed with both
a tPA and a PAI-1 specific monoclonal antibody (mab). As shown
in Figure 1, the amount of the tPA-PAI-1 complex increased with
increasing tPA concentrations until a molar excess of tPA was
reached. When the amount of tPA exceeded the amount of active
PAI-1, a 68 kDa band appeared, representing free tPA. The
highest molar concentration of tPA added without detection of
free tPA was used to calculate the molar concentration of active
PAI-1, assuming a 1:1 stoichiometric complex and a molecular
weight of 47 kDa and 68 kDa for PAI-1 and tPA, respectively.
The increase of the tPA-PAI-1 complex was verified using the
PAI-1 mab and the same dose-dependent response of the complex
was observed (data not shown).
In order to separate tPA and PAI-1 properly, SDS has to be
present in the electrophoresis. Treatment with SDS before
separation can potentially cause dissociation of the complex
and/or activation of latent PAI-1. However presence of SDS
during the separation is not expected to affect the molecular forms
of PAI-1 [19]. In this study there was no detectable difference
between samples prepared with or without SDS in the sample
buffer.
The results of the western blot in Figure 1A are also shown as
densitometric evaluations of tPA and the tPA-PAI-1 complex in
Figure 1 B and C. To clarify the course of action the details of this
specific experiment are as follows: Figure 1A (left) and 1B; platelet
count was constant in all lanes (400610
6), tPA was titrated by
50 ng per lane, ranging from 0–300 ng. Figure 1A (right) and 1C;
tPA was constant in all lanes (100 ng), platelets were titrated by
50610
6 per lane ranging from 50–150610
6 platelets. The arrow
indicates the tPA concentration used for calculating the amount of
active PAI-1. The PAI-1 antigen concentration in these specific
samples was 0.67 ng/10
6 platelets by Coaliza (0.45 ng/10
6 by
TintElize and 0.42 ng/10
6 by Immubind). The amount of active
PAI-1 in this example is 145 ng which is equimolar to 100 ng tPA
(arrow). Compared to the antigen level in 400610
6 platelets the
amount of active PAI-1 is 54% using Coaliza (81% using TintElize
and 86% using Immubind).
The average amount of functionally active PAI-1 from the 12
donors was 6565.0%. Using the average PAI-1 concentration
from the three different ELISAs (0.7960.13, 0.4860.08, and
0.6460.23 ng/10
6 for Coaliza, TintElize and Immubind respec-
tively) the fraction of functionally active PAI-1 was 81 (69)%.
Activity of PAI-1 released from activated platelets studied
by Western blot
In order to study the activity of PAI-1 released from activated
platelets, PAI-1 and the tPA-PAI-1 complex were detected by
Western blot from platelets activated by SFLLRN in the absence
or presence of a molar excess of tPA. The majority of PAI-1
appears to complex bind tPA as shown in Figure 2. It is important
to note that it is not possible to draw any conclusions of the activity
of PAI-1 from the densitometric differences between the samples.
This is due to the different affinity of the antibody (MAI-12) for the
different forms of PAI-1. Nineteen different antibodies were tested
for their affinity for active, latent, and complex bound PAI-1 but
none of them had the same affinity for the different forms, as
shown [20]. Therefore, it was not possible to use densitometric
evaluation of PAI-1 western blots to quantify the proportion of
active PAI-1.
PAI-1 activity determined using
125I-tPA
To verify the results of the Western blot analysis, we performed
a non-immunochemical assay using
125I-labelled tPA. The use of
125I-tPA and quantification by scintigraphy made it possible to
determine the amount of
125I-tPA added without further increase
of the
125I-tPA-PAI-1 complex (Figure 3). The highest concentra-
tion of
125I-tPA added without reaching maximum binding was
compared to total PAI-1 in the samples determined by ELISA as
described above. The mean PAI-1 activity in the three samples
was 5363.2%.
Using the average PAI-1 concentrations from the three ELISAs
the activity was 7266,1% (5363.2, 8265.6, and 82613.4% for
Coaliza, TintElize, and Immubind respectively). Thus, the
experiments with
125I labelled tPA confirmed the results from
the Western blot analysis with activities over 50%.
Activity of PAI-1 in lysates from sonicated or freezed/
thawed platelets
To assess whether the method of platelet disruption might affect
the PAI-1 activity the results from lysis with Triton X-100 in the
presence of tPA were compared with a series of experiments using
sonication and freezing/thawing according to the previously used
protocols. Sonication dramatically reduced the activity as shown in
Figure 4. Furthermore, there appeared to be a dose-response
relationship between the amount of sonication energy and degree
of inactivation, since the activity in samples sonicated with high
energy was considerably lower (Figure 4A) compared to samples
prepared with low energy (Figure 4B). Analysing the ratio between
densitometric intensity (model net intensity) of the tPA-PAI-1
bands, sonication with high energy reduced the activity by
approximately 90% whereas with low energy there was a 50–
60% reduction.
There was no significant difference in complex formation
between samples sonicated with or without tPA present, indicating
that sonication alone caused the reduction in activity and that it
was not merely an effect of freezing/thawing of the samples after
sonication. The reduction in activity was similar between samples
sonicated and lysed by freezing/thawing. However, samples
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in which tPA was added after lysis. Addition of 0.1% Triton X-100
to the sonicated and freeze/thawed samples did not affect the
results of the Western blot. We were unable to determine the effect
of sonication of platelets in plasma due to too high protein content
for ideal separation with SDS-PAGE (data not shown).
The effect of sonication of reactivated PAI-1 from the control
plasma from Biopool was determined by Chromolize activity assay.
The activity of the control plasma was 33.9 IU/ml. There was no
significant difference between samples sonicated 565 s and 1065s
(16.1 and 18.6 IU/ml with high energy and 29.4 and 33.6 IU/ml
with low energy respectively). By average, sonication with high
energyreducedtheactivity4963.3%andwithlowenergy764.0%.
Discussion
In the present study we reinvestigated the important issue of the
activity of platelet PAI-1 with a simple and direct functional
approach in which the reaction between tPA and PAI-1 was
studied by two assays based on reciprocating serial dilutions of tPA
and platelets. Total PAI-1 antigen was determined using
commercial ELISA kits, and tPA and tPA-PAI-1 complex was
studied by Western blot analysis as well as with autoradiography
and scintigraphy of
125I-labelled tPA. The study shows that the
Figure 1. Western blot analysis of tPA-PAI-1 complex in dilutions of platelets and tPA. A. The platelets were incubated with tPA and were
lysed in buffer with Triton X-100. Lane 1–6; constant number of platelets (in this case 400610
6) lysed in the presence of increasing amounts of tPA
(0 ng–300 ng). Lane 7–9; constant amount of tPA (100 ng) and increasing number of platelets (50610
6–150610
6). The membrane is incubated with
tPA mab PAM-3. B and C. Densitometric evaluations of the tPA and the tPA-PAI-1 complex. In fig B the band intensity is plotted against the tPA
concentration in the sample. In figure C the intensity is plotted against the number of platelets (610
6) in the sample. The arrow indicates the tPA
concentration selected for PAI-1 activity calculation.
doi:10.1371/journal.pone.0026762.g001
Figure 2. Western blot analysis of releasate from platelets
activated by SFLLRN. Platelets (200610
6) activated by 25 mM SFLLRN
in the absence or presence of an excess of tPA (1 mg). PAI-1 and tPA-
PAI-1 complex detected by the PAI-1 mab, MAI-12.
doi:10.1371/journal.pone.0026762.g002
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reported in most studies. The average PAI-1 activity was estimated
to 65% in samples analysed by Western blot and 53% in samples
analysed with
125I-labelled tPA. Our results show that both
sonication and freezing/thawing of the samples substantially
reduced the detected PAI-1 activity, which may explain the low
activity observed in studies using these lysis protocols.
Platelets contain large amounts of PAI-1 and the major part
(approximately 90%) of blood PAI-1 is found in the platelet
compartment. According to the traditional view, platelet PAI-1 is
synthesized during the megakaryocyte stage, but we have shown
that there is an on-going de novo synthesis of PAI-1 also in platelets
[13]. Regardless of tissue origin, PAI-1 is synthesized in an active
configuration but spontaneously converts to a thermodynamically
more stable inactive form. The half-life of active PAI-1 is
approximately 1–2 h at 37uC and pH 7.4 [21,22], and only the
active form of PAI-1 is capable of forming complex with, and
irreversibly inhibit tPA [23]. It has generally been assumed that
there is a similar rapid spontaneous inactivation of PAI-1 in the
megakaryocyte and platelet, which might explain the low activity
of platelet PAI-1 observed in most studies [9,10,11,12].
However, both our own data and those of other investigators
have suggested that platelets may possess a mechanism to preserve
PAI-1 in the active configuration for longer periods of time
[12,13]. To investigate this hypothesis, it is critical that the method
used to isolate PAI-1 from the platelet is able to capture the
molecule in its active form and that spontaneous inactivation
during the preparatory procedure is prevented. Conventional
enzymatic assays for PAI-1 activity are inappropriate for this
purpose and multicenter evaluations have shown that the majority
of assays fail to correctly determine the true activity of prepared
samples [24,25], a conclusion that was confirmed by inconsistent
and disparate results in our pilot studies (data not shown).
In agreement with our findings Fay et al [26] showed that the
amount of active PAI-1 in a porcine coronary artery thrombi was
36%–50%. However, this result could not be confirmed in in vitro
activated human platelets, although gentle conditions for PAI-1
isolation were used. One reason for this might be that neither tPA
was present at the time of platelet activation, nor were any other
actions taken to stabilize the active form of PAI-1 which could
therefore spontaneously have been inactivated during the long
time of extraction. To ensure an immediate capture of active PAI-
1 at the time of lysis and to circumvent the limitations of enzymatic
methods, we used an approach in which tPA was present already
when the washed platelets were lysed. By subsequent direct
detection of tPA and tPA-PAI-1 complex formation with
antibodies and
125I-tPA, the intricate interactions of the platelet
lysate with the enzymatic assays are avoided.
Both detection methods indicated that at least 50–70% of PAI-1
in washed platelets was present in an active configuration that was
biologically functional and could bind tPA. Using a conservative
definition of the amount of active PAI-1 by using the tPA
concentration immediately below the maximum of complex
formation, our approach may even have lead to an underestima-
tion of the true amount of active PAI-1. Also, calculation of the
proportion of active PAI-1 is dependent on the PAI-1 antigen
Figure 3. Autoradiography of
125I-tPA-PAI-1 complex in dilutions of platelets and
125I-tPA. Lane 1–11: increasing number of added
platelets, from 20610
6 and 500610
6, lysed in the presence of 100 ng tPA. Lane 12–20: 250610
6 platelets lysed in presence of decreasing amounts of
tPA (400 ng–25 ng).
doi:10.1371/journal.pone.0026762.g003
Figure 4. Western blot analysis of tPA-PAI-1 complex showing
the differences in PAI-1 activity depending on the lysis
method. In all samples, equal number of platelets (180610
6) was
lysed and equal amounts of tPA (500 ng) was used. The formation of
tPA-PAI-1 complex was detected by the PAI-1 mab (MAI-12). Each lane
represents different lysis conditions. Sonicated samples on membrane A
was lysed with high energy on setting 7. On membrane B, sonicated
samples were lysed with milder sonication on setting 2. To lane 1, 5, 6,
and 7 tPA was present during lysis. In lane 2, 3, and 4 tPA was added to
the samples after lysis. Lysis conditions of the platelets: Lane 1A, 1B: in
lysis buffer containing 0.1% Triton X-100 with tPA present. Lane 2A, 2B:
in homogenisation buffer lysed by sonication. Lane 3A, 3B: in Pipes
buffer lysed by sonication. Lane 4A, 4B: in Pipes buffer lysed by freezing
and thawing. Lane 5A, 5B: in Pipes buffer lysed by sonication with tPA
present. Lane 6A: in Pipes lysed by freezing and thawing with tPA
present. Lane 6B 7B and 8B: 6 same as sample 1, 7 and 8 same as 3 and
4, but with 0.1% Triton X-100 added after sonication or freezing/
thawing. The results of the densitometry measurements are presented
as arbitrary units with samples lysed by Triton X-100 set to 1.0.
doi:10.1371/journal.pone.0026762.g004
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different ELISA assays which detect all molecular forms of PAI-1
with similar efficiency [11,20,27,28]. We report the activity
concentrations calculated from the assay that measured the
highest antigen concentrations (Coaliza) to avoid a possible
overestimation of the activity level. The ELISA assays are
optimised for plasma samples, but the concentration of platelet
PAI-1 is in accordance with previous reported levels [9,11,17] and
variations between the assays are probably due to inter-assay
variations previously described [29].
A limitation of the functional assay approach is that it only gives
an approximate estimate of the activity, since it is limited by the
tPA titration intervals. By decreasing the intervals, a 10%
difference in the concentration of active PAI-1 could be detected.
Toshedlighton possible mechanismsbehind thelowactivityrates
observed in previous studies [9,10,11,12], we investigated the
influence of commonly used pre-analytic procedures. First, we
studiedtheeffectofsonication,sincearecentstudyhasdemonstrated
that energy levels as low as 30 W may cause protein damage [14]
and it is conceivable that a thermodynamically unstable molecule,
such as active PAI-1, is more susceptible to inactivation. Indeed, our
results showed that even reactivated plasma PAI-1, stabilized by low
pH, is very sensitive to sonication; its activity was reduced by
approximately 50% with an energy load of 30 W, which is 5-fold
lower than the energy used for platelet lysis [9]. Using the high-
energy sonication protocol employed in previous reported studies,
we found that platelet PAI-1 activity was reduced approximately
90%. Taken together, with the activity rates observed in the present
study, one would expect sonication to reduce platelet PAI-1 activity
to 7–8%, i.e. to similar levels as reported in previous studies.
The magnitude of the reduction in PAI-1 activity was similar
when freezing/thawing was used for platelet lysis. However,
whereas the reduced activity by sonication was independent of
whether tPA was added before or after lysis, the underestimation of
activity by freezing/thawing could partially be prevented by adding
tPA before lysis. Another common procedure for platelet disruption
is to use detergents such as Triton X-100 [17,30]. However, it has
beenshown that TritonX-100 decreases the half-life of active PAI-1
markedly, and 0.2% Triton X-100 decrease the functional half-life
of PAI-1 to less than 1 minute at 37uC [15,16]. Therefore, also with
such protocols it is crucial to add tPA before lysis. Since addition of
Triton X-100 is not physiological and may facilitate the binding of
tPA and PAI-1, we investigated if Triton X-100 affected the results
of the Western blot analysis. However, when Triton X-100 was
added to the platelets lysed by sonication and freezing/thawing no
such enhancement was observed (figure 4B).
A potential concern in the present study could have been that
the procedure we used in some way could have reactivated PAI-1
although it was in fact inactive in vivo. In vitro PAI-1 can be
reactivated by denaturants such as SDS, guanidine HCl, and urea
[31], and it has also been suggested that negatively charged
phospholipids exposed on the surface of activated platelets could
reactivate PAI-1 [32]. On the other hand, it has been reported that
SDS may cause dissociation of the tPA-PAI-1 complex [19]. To
rule out the possibility that our results were due to reactivation
and/or dissociation of the tPA-PAI-1 complex formed, we
performed a series of experiments both with and without SDS in
the loading buffer before electrophoresis. However, these studies
showed no detectable differences in PAI-1 activity whether SDS
was present or not. This is in agreement with a previous study
reporting that the SDS-activatable form of PAI-1 might not be
present in human platelets [33].
How, then, could the activity of PAI-1 be preserved for such a
prolonged period of time in the platelet? A potential mechanism
has been suggested by Lang and Schleef, who showed that platelets
possess a unique mechanism for stabilization of active PAI-1, by
packaging together with other large a-granule proteins in a
calcium-dependent manner [12]. Active PAI-1 in plasma is
stabilized by binding to vitronectin [34,35] which has also been
detected in platelet a-granules. However, some studies have failed
to detect the vitronectin-PAI-1 complex in platelets [12,17] and it
is therefore controversial whether vitronectin is the stabilizing
factor of PAI-1 in platelets. This issue remains to be evaluated.
From a clinical perspective, there is compelling evidence that
platelet-derived PAI-1 has an important physiologic and patho-
physiologic role in making platelet-rich blood clots resistant to both
endogenous and pharmacologicalthrombolysis [5,6,8]. Despite this,
most previous studies have reported activity levels of platelet PAI-1
that are probably far too low to explain its putative functional role.
Our results may provide the missing clue to reconcile the seemingly
contradictory findings. Taken together, our observations suggest
that the large amount of PAI-1 stored in platelets is functional and
thus capable to inhibit fibrinolysis, which may explain their
observed role in clot stabilization. The present findings suggest that
pre-analytic preparatory procedures have contributed to the
underestimation of platelet PAI-1 activity in previous studies.
Materials and Methods
Subjects and Ethics Statement
Platelets were collected from healthy subjects that were not
allowed to take acetyl salicylic acid or non-steroid anti-inflamma-
tory drugs 10 days prior to the investigation. All subjects were
given written and oral information and gave their verbal consent,
in accordance with the study protocol that was approved (O ¨ 498-
03) by the Ethics Committee of the University of Gothenburg. All
samples were handled anonymously and were not identifiable
during the preparations making written consent uncalled for.
Verbal consent was approved by the Ethics Committee of the
University of Gothenburg.
Platelet isolation
Platelets were isolated, washed, counted, and pelleted as
described in detail previously [13]. In brief, 85 ml blood from
each of 12 subjects was drawn in acid-citrate-dextrose solution
containing prostaglandin E1 (PGE1). Platelet-rich plasma was
prepared by repeated centrifugation at room temperature. After
pelleting, the platelets were washed in Pipes-buffer containing
PGE1. Platelets were counted, and pelleted and the supernatant
was discarded. Platelets were immediately used for subsequent
preparation and analysis.
Determination of total amount of platelet PAI-1 antigen
Between 50 to 100610
6 platelets were lysed in lysis buffer
(50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, 1 mM EDTA,
0.1% TritonH X-100 at pH 7.4) for 30 min on ice. The platelet
lysates were centrifuged at 10 0006g for 10 minutes at 4uCt o
remove cell debris, and the supernatants were stored at 280uC
until analysis. The total amount of PAI-1 antigen in platelet lysates
was determined by CoalizaH PAI-1 ELISA (Chromogenix, Milan,
Italy), according to the manufacturers’ instructions. The samples
were diluted with the buffers supplied as well as in PAI-1 depleted
plasma (Biopool, Umea ˚, Sweden). Possible interference of the lysis
buffer was excluded by re-analysis of the standard diluted with lysis
buffer, and no interference was detected.
Two additional ELISA kits for PAI-1 antigen determinaition were
alsousedTintElizeHPAI-1(Biopool,Umea ˚,Sweden),andImubindH
Plasma PAI-1 (American Diagnostica, Stamford, CT, USA).
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analysis
Due to variations in platelet PAI-1 levels and platelet yield
from each subject the amount of platelets, tPA, and the lysis
volume had to be optimized in each preparation in order to
obtain optimal tPA and PAI-1 concentrations for detection with
Western blot. From each of the 12 donors two series of
experiments were performed in which either tPA or the number
of platelets were kept constant. In the average experiment, first, a
total of 300610
6 platelets were used in ten sample preparations.
The platelet pellets were resuspended in 250 ml Pipes-buffer [13]
and serially increasing amounts of sc-tPA (Biopool, Umea ˚,
Sweden), in steps from 25 to 300 ng, were added. In the other
series of experiments, a constant amount of tPA (typically 100 ng)
was used in the presence of increasing numbers of platelets (in ten
steps from 25 to 600610
6). After addition of tPA the platelets
were immediately lysed at room temperature (RT) by adding
106lysis buffer (25 ml).
In additional experiments, the platelets were activated for
30 minutes by incubation with the PAR receptor agonist SFLLRN
(24 mM) (Bachem, Bubendorf, Switzerland) both in the absence or
presence of an excess of tPA.
Subsequently, the different platelet lysate or releasate samples
were centrifuged at 10 000 g for 10 minutes at 4uC and the
supernatants were diluted 1:2 in Laemmli sample buffer with or
without 35 mM SDS [36], loaded on 10% Tris-Glycine-
polyacrylamide gels in Tris-glycine SDS runningbuffer and
immediately separated. Proteins were blotted onto PVDF
membranes (Hybond
TM-P Amersham Biosciences, Buckingham-
shire, UK) that was subsequently incubated with either a tPA mab
PAM-3 (0.3 mg/ml) or a PAI-1 mab MAI-12 (0.5 mg/ml) (Biopool,
Umea ˚, Sweden). After incubation with a peroxidase labelled
secondary antibody, bands were visualized with Super SignalH
West Pico Chemiluminescent Substrate (Pierce Perbio, Rockford,
IL, USA).
To determine the amount of PAI-1 in complex with tPA (i.e.
active PAI-1) in the platelet lysate we identified the sample with
the highest tPA concentration added without detection of free tPA
at 68 kDa. The further increase of the tPA-PAI-1 band in the next
lane was used as verification that no free tPA was present but
below the detection limit of the assay in the previous lane. Serial
dilutions of tPA and PAI-1 were performed to determine the
detection limit of the Western blot analysis which was found to be
approximately 2.5 ng for both tPA and the tPA-PAI-1 complex
(data not shown).
Functional assay of active platelet PAI-1 by
125I labelled
tPA
Labelling of 100 mg tPA (100 ml) was performed using 500 mCi
Na
125I according to the Iodogen method [37] using PierceH
Iodination Reagent (Pierce Perbio, Rockford, IL, USA). Labeled
tPA (626000 cpm/mg tPA) was separated from free Na
125I by gel
filtration on a PD-10 column and eluted in 1.25 ml Phosphate
Buffered Saline (Gibco BRL, Life Technology, Paisley, UK)
containing 0.01% Tween 20 (to avoid adsorption to plastic ware
because of the low tPA concentration). The concentration of tPA
after labelling was determined using both total protein assay (Bio-
Rad, Hercules, CA, USA) and ELISA (TintElizeH tPA, Biopool).
Recovery of functional tPA (i.e. ability to complex PAI-1) was
evaluated by addition of 10 to 10 000 fold molar excess of active
rhPAI-1 (expressed in Chinese Hamster Ovary cells [38]) and
labelling was shown to reduce the activity of tPA by 40%.
Platelets from 3 subjects were prepared and lysed in lysis buffer
in the presence of
125I-labelled tPA, as described. The samples
were diluted in sample buffer 1:2 (without SDS) and separated on
10% Tris-Glycine gels. After autoradiography the tPA and tPA-
PAI-1 complex were cut out and quantified by analysis on a
Packard Cobra II Auto Gamma counter (Perkin-Elmer, Downers
grove, Il, USA).
Comparison of different methods for lysis of platelets
Three separate experiments were performed to evaluate the
effect of different lysis methods on the platelet PAI-1 activity.
Platelets were isolated as described, 180610
6 platelets were
pelleted, re-suspended, and lysed in accordance with the
previously described protocols [9,12,30]. Platelets were re-
suspended in 1 ml homogenisation buffer [12] (150 mM NaCl,
20 mM Tris-HCl, pH 7.5, containing 2.5 mM EDTA 100 nM
PGE1, and 5.5 mM D-glucose), 1 ml autologous plasma [9] or
1 ml Pipes-buffer with or without 500 ng tPA. The platelets were
lysed either by freezing/thawing [11,30] or by sonication
[9,10,12]. Platelet samples were also lysed with 0.1% Triton X-
100, as described. The different combinations of lysis methods and
buffers are described in detail in the legends to Figure 4.
Sonication was performed using a Branson SonifierH 250
(Branson Ultrasonic Corporation, Danbury, CT, USA) equipped
with a microtip. The instrument frequency was 20 kHz and
sonication was performed on ice for 565 s in one minute intervals
with the instrument setting on either 2 or 7 (corresponding to an
effect of approximately 10 and 30 W, respectively). The lysates
were centrifuged at 10 000 g for 10 min at 4uC and the
supernatants were stored at 280uC until analysis.
tPA was added to the samples lysed without tPA present and
after a 15 min incubation at RT, Western blot analysis was
performed as described. In two separate experiments 0.1% Triton
X-100 was added to the samples after sonication or freezing/
thawing to exclude the possibility that Triton X-100 interferes with
the results or that incomplete lysis is the cause of low activity.
Quantitative scanning densitometry was performed using
Kodak 1D Image Analysis software to estimate the relative
differences in tPA-PAI-1 complex concentration in samples
prepared with different lysis methods. The model net intensity of
tPA-PAI-1 in sonicated or freeze/thawed samples was related to
model net intensity of the tPA-PAI-1 from platelets lysed with
Triton X-100.
We also performed an experiment of the effects of sonication on
plasma PAI-1 activity. PAI-1 Activity Control Plasma Set from
Biopool (Umea ˚, Sweden) was prepared according to instructions
and was sonicated on ice. Samples were sonicated in duplicates
565 s on setting 2 or 7 in one minute intervals, or 1065so n
setting 2 or 7 in one minute intervals. Plasma PAI-1 activity was
subsequently analyzed by Chromolize
TM PAI-1 activity assay
(Biopool, Umea ˚, Sweden).
Statistics
Results are presented as mean 6 standard error of the mean.
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